Results for this period
Full year1 October 2025 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The factors affecting changes in results were the consolidation of Faskia Holdings Co., Ltd. and its 3 subsidiaries, increased revenue in other areas, a decrease in large projects associated with the construction, relocation and reorganization of medical institutions and other facilities, higher personnel expenses, and the absence of the impact of share acquisition-related expenses recognized in the fiscal year ended September 2026.
No material events or circumstances related to the going concern assumption, and no notes regarding the going concern assumption, apply.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025 to 30 September 2026 |
| Net Sales | 46,910 Million yen (YoY +118.3%) |
| Operating profit | 807 Million yen (YoY +180.2%) |
| Ordinary income | 748 Million yen (YoY +142.5%) |
| Profit attributable to owners of the parent | 346 Million yen (YoY +126.9%) |
| Net income per share | ¥58.60 |
| Operating Margin | 1.7% |
| Equity ratio | End of the current fiscal period 25.9% / End of previous period 51.8% |
| Total assets | 22,730 Million yen |
| Net assets | 6,079 Million yen |
| Cash flows from operating activities | 1,655 Million yen |
| Cash flows from investing activities | -4,332 Million yen |
| Cash flows from financing activities | 4,349 Million yen |
| Cash and cash equivalents at end of period | 6,418 Million yen |
| Full-year earnings forecast | Net Sales 48,000 Million yen (YoY +2.3%) / Operating profit 900 Million yen (YoY +11.4%) / Ordinary income 850 Million yen (YoY +13.5%) / Net income 500 Million yen (YoY +44.2%) |
| Annual Dividend Forecast | ¥17.00 → ¥22.00 |
| Payout ratio | the fiscal year ending September 2026 29.0% / Forecast for the fiscal year ending September 2027 26.1% |
| Segment revenue | Medical Total Solution Business ¥21,283,813 thousand (YoY +5.1%) / Remote Diagnostic Imaging Services Business ¥821,990 thousand / Minimally Invasive Medical Device Sales business ¥22,279,821 thousand / Rental Business ¥638,117 thousand |
| Segment profit | Medical Total Solution Business ¥249,316 thousand (YoY -19.0%) / Remote Diagnostic Imaging Services Business ¥66,099 thousand (YoY -4.5%) / Minimally Invasive Medical Device Sales business ¥381,168 thousand / Rental Business ¥81,247 thousand |
| Depreciation and amortization | ¥431,531 thousand |
| Disclosure regarding the going concern assumption | No material events or circumstances related to the going concern assumption, and no notes regarding the going concern assumption, apply. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 4 / Company name ファスキアホールディングス株式会社, 株式会社フォーム, 株式会社シンコム, 中京三洋株式会社 / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable items |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 5,922,000 shares |
| Treasury Shares at Period-End | 237 shares |
| Factors Behind Changes in Business Performance | The factors affecting changes in results were the consolidation of Faskia Holdings Co., Ltd. and its 3 subsidiaries, increased revenue in other areas, a decrease in large projects associated with the construction, relocation and reorganization of medical institutions and other facilities, higher personnel expenses, and the absence of the impact of share acquisition-related expenses recognized in the fiscal year ended September 2026. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The consolidation of Faskia Holdings Co., Ltd. and its 3 subsidiaries, increased revenue in other areas, and initiatives aimed at expanding the company’s scale and generating stable results contributed to higher revenue and earnings. Meanwhile, in the Medical Total Solutions business, lower profits were attributable to a decrease in large projects and higher personnel expenses.